Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 32217764)

  • 1. Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort.
    Bevins N; Sun S; Gaieb Z; Thorson JA; Murray SS
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing.
    Wang HY; Deng L; Li YQ; Zhang X; Long YK; Zhang X; Feng YF; He Y; Tang T; Yang XH; Wang F
    Cancer Res Treat; 2021 Oct; 53(4):973-982. PubMed ID: 33677848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing.
    Heydt C; Rehker J; Pappesch R; Buhl T; Ball M; Siebolts U; Haak A; Lohneis P; Büttner R; Hillmer AM; Merkelbach-Bruse S
    Sci Rep; 2020 Jul; 10(1):11387. PubMed ID: 32647293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
    Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
    JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB
    Ramos-Paradas J; Hernández-Prieto S; Lora D; Sanchez E; Rosado A; Caniego-Casas T; Carrizo N; Enguita AB; Muñoz-Jimenez MT; Rodriguez B; Perez-Gonzalez U; Gómez-Sánchez D; Ferrer I; Ponce Aix S; Nuñez Buiza Á; Garrido P; Palacios J; Lopez-Rios F; Garrido-Martin EM; Paz-Ares L
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessments of tumor mutational burden estimation by targeted panel sequencing: A comprehensive simulation analysis.
    Li D; Wang D; Johann DJ; Hong H; Xu J
    Exp Biol Med (Maywood); 2023 Nov; 248(21):1918-1926. PubMed ID: 38062992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.
    Endris V; Buchhalter I; Allgäuer M; Rempel E; Lier A; Volckmar AL; Kirchner M; von Winterfeld M; Leichsenring J; Neumann O; Penzel R; Weichert W; Glimm H; Fröhling S; Winter H; Herth F; Thomas M; Schirmacher P; Budczies J; Stenzinger A
    Int J Cancer; 2019 May; 144(9):2303-2312. PubMed ID: 30446996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
    Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
    Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer.
    Park S; Lee C; Ku BM; Kim M; Park WY; Kim NKD; Ahn MJ
    BMB Rep; 2021 Jul; 54(7):386-391. PubMed ID: 34154699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'.
    Wu HX; Wang ZX; Zhao Q; Wang F; Xu RH
    J Immunother Cancer; 2019 Aug; 7(1):206. PubMed ID: 31387639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis.
    Buchhalter I; Rempel E; Endris V; Allgäuer M; Neumann O; Volckmar AL; Kirchner M; Leichsenring J; Lier A; von Winterfeld M; Penzel R; Christopoulos P; Thomas M; Fröhling S; Schirmacher P; Budczies J; Stenzinger A
    Int J Cancer; 2019 Feb; 144(4):848-858. PubMed ID: 30238975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
    Chan TA; Yarchoan M; Jaffee E; Swanton C; Quezada SA; Stenzinger A; Peters S
    Ann Oncol; 2019 Jan; 30(1):44-56. PubMed ID: 30395155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of low tumor content on tumor mutational burden estimation by whole-exome sequencing and targeted panel sequencing.
    Zhang W; Wang R; Fang H; Ma X; Li D; Liu T; Chen Z; Wang K; Hao S; Yu Z; Chang Z; Na C; Wang Y; Bai J; Zhang Y; Chen F; Li M; Chen C; Wei L; Li J; Chang X; Qu S; Yang L; Huang J
    Clin Transl Med; 2021 May; 11(5):e415. PubMed ID: 34047470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benchmarking bioinformatics approaches for tumour mutational burden evaluation from a large cancer panel against whole-exome sequencing.
    Pang J; Xia H; Mi S; Zhang W; Pendrick D; Freeman C; Fernandes H; Mansukhani M; Hsiao SJ
    J Clin Pathol; 2023 Apr; 76(4):276-280. PubMed ID: 35906043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project.
    Vega DM; Yee LM; McShane LM; Williams PM; Chen L; Vilimas T; Fabrizio D; Funari V; Newberg J; Bruce LK; Chen SJ; Baden J; Carl Barrett J; Beer P; Butler M; Cheng JH; Conroy J; Cyanam D; Eyring K; Garcia E; Green G; Gregersen VR; Hellmann MD; Keefer LA; Lasiter L; Lazar AJ; Li MC; MacConaill LE; Meier K; Mellert H; Pabla S; Pallavajjalla A; Pestano G; Salgado R; Samara R; Sokol ES; Stafford P; Budczies J; Stenzinger A; Tom W; Valkenburg KC; Wang XZ; Weigman V; Xie M; Xie Q; Zehir A; Zhao C; Zhao Y; Stewart MD; Allen J;
    Ann Oncol; 2021 Dec; 32(12):1626-1636. PubMed ID: 34606929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of high tumor mutational burden in solid tumors and challenges for biomarker application.
    McNamara MG; Jacobs T; Lamarca A; Hubner RA; Valle JW; Amir E
    Cancer Treat Rev; 2020 Sep; 89():102084. PubMed ID: 32738738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels.
    Ramarao-Milne P; Kondrashova O; Patch AM; Nones K; Koufariotis LT; Newell F; Addala V; Lakis V; Holmes O; Leonard C; Wood S; Xu Q; Mukhopadhyay P; Naeini MM; Steinfort D; Williamson JP; Bint M; Pahoff C; Nguyen PT; Twaddell S; Arnold D; Grainge C; Basirzadeh F; Fielding D; Dalley AJ; Chittoory H; Simpson PT; Aoude LG; Bonazzi VF; Patel K; Barbour AP; Fennell DA; Robinson BW; Creaney J; Hollway G; Pearson JV; Waddell N
    ESMO Open; 2022 Aug; 7(4):100540. PubMed ID: 35849877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing panel-based tumor mutational burden (TMB) measurement.
    Budczies J; Allgäuer M; Litchfield K; Rempel E; Christopoulos P; Kazdal D; Endris V; Thomas M; Fröhling S; Peters S; Swanton C; Schirmacher P; Stenzinger A
    Ann Oncol; 2019 Sep; 30(9):1496-1506. PubMed ID: 31268125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
    Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
    J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.